Immunic (NASDAQ:IMUX) is a biotechnology company focused on developing therapies targeting immune-mediated and autoimmune diseases. With a keen eye on innovating treatment options, Immunic aims to address unmet medical needs in conditions such as ulcerative colitis, Crohn's disease, psoriasis, and multiple sclerosis. Their projects span from early discovery to clinical development stages, leveraging their expertise to potentially deliver novel drugs that can significantly improve patients' lives. Immunic’s objectives include advancing their pipeline through clinical trials, ensuring safety and efficacy of their treatments, and fostering partnerships that could expedite the delivery of their therapies to patients worldwide. The company's dedication to research and development is at the core of its mission to transform the therapeutic landscape of immune-mediated diseases.